Hi Manhar,

1. Opening Account is easy, you just have to fill in the details

2. The platform seems okay (not the best UI), it goes give information about your investments.

3. I haven’t explored the Secondary Market much, as I mostly placed my bids directly from my account and not from NDS-OM. I am yet to sell any bonds and will need to some poking around to figure out.
   

   

4. None for buying, remains to be seen if there’s any for selling.

5. No. Nothing. You only see generic details about the bonds you have purchased not the dynamic info.

6. Not sure about all of them, I’ve seen fixed, floating and zero coupon bonds listed so far.

7. Its been really basic, I need to explore NDS-OM more maybe that will make my experience better.

Disclosure : I’m a rookie when it comes to bond investing and RBI Retail platform will frustrate beginners.

Apologies everyone for the delayed response - July was a very busy month for me on the professional front and in August I was traveling abroad for majority of the time.

@sougataG have answered this question here . Regarding sharing the template - I would have to spend a lot of time to scrub the data as I have multiple sheets with Equity, Mutual Funds, NPS, etc. details in it. Not sure that would be so easy for me.

@Mudit.Kushalvardhan - I’m currently holding 30 scrips, with 95% allocation in the top 25. I will likely always hold more than 20 stocks. I believe in adequate diversification as I’m not the promoter managing the business, no matter how much I deep-dive/analyze/study any company - a business can face various unseen and unimaginable risks. Diversification is your only free lunch in the market.

Also I recently posted here - the number of stocks in your portfolio has no correlation with your portfolio returns.

@Investor_No_1 - I’ve been adding HCL Tech aggressively throughout 2022 - avg buy price ~1010. Recent correction seems to be offering another good opportunity. I’d love to buy midcap IT but they are either at quite stretched valuations (anything above 30x P/E is relatively high multiple) or not as robust business model as the large cap IT plays.

Both Rajshree Polypack and Beta Drugs have their threads (RPPL quite a detailed one) on VP. I think most of the information about these companies is covered there.

The management of Rajshree has a great execution track record in my view. All the planned capex over the past 2-3 years is now bearing fruit along the lines of management guidance. The last quarter had the highest ever quarterly sales in the company’s history. Management has also done a preferential issue at a price of 193 for the next phase of company’s growth.

Beta Drugs is a branded generics oncology play with the main advantage of it being a pea sized fish in an ocean. There is massive opportunity/runway for growth and the management has delivered fabulously so far. With Indian pharma companies, I think scale becomes a big challenge and I don’t like any large sized pharma companies given the intense competition, regulatory hurdles and challenges. In pharma, being small in size is a massive advantage in my view. The management / corporate governance of Beta Drugs is average in my view - they just about meet expectation. Promoters have taken considerable salary increase with exponential growth in profits (not a red flag but obviously not the best corporate governance).

I am studying Websol Energy System Ltd. The company makes solar cells and is increasing its capacity by 7 times (from the current 250 MW to 1.8 GW) while upgrading its solar cell tech from multi-crystalline technology to Mono PERC and TOPCon. As per the annual report, 1200 MW capacity would come live by end of this year.

The company decided to take voluntary losses in Q1 by scraping the existing technology and replacing the legacy equipment with cutting-edge alternatives. The losses would continue for another quarter or so. Expected sharp rebound in 2023-24.

Not sure if it is part of the above capacity expansion plan but early this month, Websol announced JV with AMP Energy India, part of Amp Energy Group for 1.2GW capacity of solar cell manufacturing.

Disclaimer: Studying it and would appreciate any further thoughts. The company thread isn’t very active.

Dmart has negative FCF, because it puts back the cash generated into the business, taking no debt. So we have to know the reason why there is no free cash.